Background
==========

Increasing evidence suggests that the pathophysiology of COPD is characterized by the interaction between several factors, including local and systemic inflammation.[@b1-copd-12-2261],[@b2-copd-12-2261] IL-6 plays a central role in the inflammatory process underlying COPD, with increased concentrations reported in plasma, sputum, and exhaled breath of patients with COPD, especially during exacerbations.[@b3-copd-12-2261]--[@b7-copd-12-2261] IL-6 stimulates the synthesis of acute phase proteins, but also affects platelet count by stimulating the differentiation of megakaryocytes into platelets and possibly by stimulating thrombopoietin production.[@b8-copd-12-2261]--[@b12-copd-12-2261]

It has been shown that platelets actively participate in inflammation in several conditions.[@b13-copd-12-2261] Upon activation, platelets release chemokines from their α-granules such as MIF, CXCL4, CXCL7 or CXCL5 which play a role in inflammatory processes.[@b14-copd-12-2261] CXCL5 is a chemokine of potential importance in regulation of lung inflammation, by modulating neutrophil transepithelial and transendothelial migration and accumulation in the airspace.[@b15-copd-12-2261] Furthermore, platelets regulate MMPs' activity which significantly contributes to inflammation. Platelets regulate MMPs both directly by secretion of the proteases and their inhibitors, and indirectly by influencing the behavior of other cells such as neutrophils and monocytes.[@b16-copd-12-2261] Platelet-derived CD40L, which is shed from the platelet surfaces by MMPs, induces MT-1-MMP, MMP-1, MMP-2, and MMP-9 on endothelial cells.[@b17-copd-12-2261],[@b18-copd-12-2261] There is evidence proving the role of these MMPs in the pathophysiology of COPD.[@b19-copd-12-2261]--[@b23-copd-12-2261]

The routinely available indices which describe platelets' morphology and function are the platelet count (PLT), the platelet-to-lymphocyte ratio (PLR), the mean platelet volume (MPV), and the platelet distribution width (PDW). Thrombocytopenia was associated with poor outcomes in acute exacerbations of COPD.[@b24-copd-12-2261] On the other hand, thrombocytosis may be associated with increased short- and long-term mortality after exacerbations.[@b25-copd-12-2261] PLR describes the correlation between changes in levels of platelets and lymphocytes. PLR has been reported to play a significant role in cardiovascular diseases,[@b26-copd-12-2261],[@b27-copd-12-2261] diabetic ketoacidosis,[@b28-copd-12-2261] and numerous neoplasms.[@b8-copd-12-2261],[@b12-copd-12-2261],[@b29-copd-12-2261]--[@b40-copd-12-2261] MPV reflects changes in either the level of platelet stimulation or the rate of platelet production.[@b41-copd-12-2261] It has been assessed as an inflammatory marker in several diseases.[@b42-copd-12-2261]--[@b44-copd-12-2261] COPD patients, during acute exacerbation and in stable phase, have lower MPV compared with healthy controls, and the MPV increases once patients have recovered from exacerbation.[@b45-copd-12-2261] PDW is an index of platelets' volume heterogeneity[@b46-copd-12-2261] and may increase in platelets' activation.[@b47-copd-12-2261] The role of PDW has been assessed in several conditions, such as acute gangrenous appendicitis, carotid artery stenosis, coronary artery disease, angina pectoris, idiopathic pulmonary hypertension, ovarian torsion, and preeclampsia.[@b48-copd-12-2261]--[@b56-copd-12-2261] PDW can serve as useful prognostic factor for long-term mortality in patients with acute myocardial infarction and was found to be an independent risk factors for cardiovascular mortality.[@b57-copd-12-2261] Because hypercoagulation may play a significant role in conditions associated with worse survival of patients with COPD,[@b58-copd-12-2261],[@b59-copd-12-2261] we hypothesized that PDW may be associated with survival in these patients. The objective of this study was to evaluate the mortality rate of patients with COPD with and without an abnormal PDW.

Methods
=======

From the electronic archive of the Campus Bio-Medico Hospital in Rome, Italy, between March 2006 and December 2014, we identified 288 patients with post-bronchodilator forced expiratory volume in 1 second to forced vital capacity ratio (FEV~1~/FVC) \<0.7 and for whom information on vital status could be obtained from the regional death registry. Subsequently, we selected patients with a blood cell count performed within 2 weeks of the index spirometry (N: 92).

We excluded patients with conditions that, based on the available evidence, may affect PDW: acute exacerbation of COPD, any active acute inflammation, connective tissue disorder, diabetic ketoacidosis, recent history of myocardial infarction, end-stage renal disease, history of any active malignancy, and hematological system diseases, or blood transfusion in the last 2 months.

Demographic data, medical history, and routine laboratory measurements, including white blood count, neutrophils, lymphocytes, PLT, MPV, and PDW, were collected from the digital database of medical records of Campus Bio-Medico di Roma.

Pulmonary function tests (PFTs) including vital capacity (VC), FVC, FEV~1~, FEV~1~/FVC ratio, forced expiratory flow between 25% and 75% of VC (FEF 25--75), peak expiratory flow (PEF), total lung capacity (TLC), and residual volume, were collected from the digital database of medical records of Campus Bio-Medico di Roma. PFTs were performed with the water-bell volume spirometry device between March 2006 and December 2012 by the same technician. All lung function parameters were measured according to the American Thoracic Society/European Respiratory Society guidelines.[@b60-copd-12-2261]--[@b63-copd-12-2261]

Continuous data are presented as the mean with 95% CI, except survival that was presented as median. Variables were compared after grouping patients according to the laboratory upper limit of PDW, using *t*-test for normally distributed continuous data, and Mann--Whitney *U* test for not normally distributed continuous data. Categorical variables were compared using chi-square test with Yates' continuity correction.

Survival analysis was performed after grouping patients according to the laboratory normal limit for PDW values. Kaplan--Meier analysis and log-rank test were used to compare survival curves. Multivariable analyses were performed using Cox proportional hazards regression to adjust for age, comorbidities, and FEV~1~.

Data were analyzed using R software for MacOS (R Core Team \[2016\]. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria).

The protocol of the study was approved by the Ethics Committee of the Campus Bio-Medico University.

Results
=======

Seventy-nine patients met the inclusion criteria. The flow chart of sample selection is reported in [Figure 1](#f1-copd-12-2261){ref-type="fig"}. Most patients were GOLD stage II (49.4%), ex-smokers (62.5%), and had comorbidities (90%). Mean age of the study population was 73.6 (95% CI: 72.32, 74.95). The overall male-to-female ratio was 1.93:1. The means of baseline values of the study population are presented in [Table 1](#t1-copd-12-2261){ref-type="table"}.

Ten patients presented values of PDW above 16 fL, which was the upper limit of normality for our laboratory. There were no differences in age and gender distribution between the groups. Participants with higher PDW showed significantly lower FEF 25--75 and PEF values compared to those with normal PDW -- both in absolute values, and expressed as percent of reference value ([Table 2](#t2-copd-12-2261){ref-type="table"}).

Patients with high PDW had worse survival compared to patients with normal PDW, with a median survival time of 743 days compared to 1,305 days of patients with normal PDW ([Figure 2](#f2-copd-12-2261){ref-type="fig"}). Log rank test showed significant differences between groups (chi-square =4.9; *P*=0.025). Abnormal PDW values were associated with an RR of death of 3.18 (95% CI 0.6, 7.79; *P*=0.07). The HR for unadjusted Cox regression was 4.34 (95% CI: 1.072, 17.6; *P*=0.04) and HR after adjustment for gender, age, comorbidities, and FEV~1~% was 4.59 (95% CI: 1.1, 19.19; *P*=0.04).

Discussion
==========

In our study, we found that elevated PDW was associated with increased risk for mortality in COPD patients. This result was confirmed after adjustment for age, comorbidities, and FEV~1~%, suggesting that in our sample PDW was an independent risk factor for mortality.

Activation of platelets causes morphological changes, including pseudopodia formation. Pseudopodium formation enhances platelet--surface interactions (adhesion) and platelet--platelet interaction (cohesion).[@b64-copd-12-2261] Progressively activated platelets with pseudopodia formation have heterogeneous size, and PDW may increase.[@b47-copd-12-2261] The association of PDW with survival may be hypothetically linked with hypercoagulation, which plays a significant role in conditions associated with survival in COPD, eg, acute myocardial infarction and other forms of ischemic heart disease.[@b58-copd-12-2261],[@b59-copd-12-2261] According to Wang et al, elevated PDW is a risk factor for pulmonary embolism and may be observed in COPD patients with this condition.[@b65-copd-12-2261]

Our results are in line with other evidence which shows that PDW may be a marker of COPD exacerbations,[@b66-copd-12-2261] while patients with stable COPD do not seem to have higher PDW compared to controls.[@b67-copd-12-2261] Furthermore, the use of antiplatelet drugs was associated with improved survival in oxygen-dependent COPD patients.[@b68-copd-12-2261]

While we excluded patients with diseases with an obvious impact on PDW or inflammation, in our sample, comorbidities were common, eg, prevalence of diabetes mellitus was 23%. Makhlouf et al showed that COPD patients with diabetes mellitus had significantly higher PDW compared to healthy controls, but there was no difference in PDW between COPD patients with and without diabetes mellitus.[@b69-copd-12-2261]

We found significantly lower values of FEF 25--75 and PEF among patients with elevated PDW. This is a novel finding in a population of patients with COPD. Indeed, FEF 25--75 reflects the expiratory flows in peripheral airways, whereas PEF is strictly dependent upon the strength of expiratory muscles. Thus, these findings, though preliminary in nature, suggest that higher PDW, as a marker of inflammatory and hypercoagulable status, is linked to lung metabolism/inflammation and sarcopenia. Unfortunately, we lacked additional information, such as breath pattern analysis and direct measurement of respiratory muscle strength, to test this hypothesis. However, we think that it is unlikely that PDW per se has any direct effect on pulmonary function. The associations that we have found are most likely due to platelet morphology acting as a marker for some other biological process, such as inflammation. Due to the retrospective character of our study, causal relationship cannot be verified, and our results must also be interpreted in light of the fact that both of these parameters have limited clinical value in COPD, while we found no difference in spirometric parameters known to have important prognostic significance (FEV~1~, FVC). Measurement of FEF 25--75 does not contribute to clinical decision making.[@b70-copd-12-2261] PEF is recorded in the first tenth of a second of forced expiration, while FEV~1~ continues to record forced expiration for a further 0.9 s, therefore FEV~1~ records what happens to expired air after peak flow is reached. It is in this component of forced expiration that the changes characteristic of COPD are observed.[@b71-copd-12-2261]

There are some limitations of our study that need to be taken into account. Our sample size is relatively small and we could not fully investigate the relationship between PFT and PDW. Furthermore, our study is a retrospective analysis and we have to be aware of a risk of selection bias.

Conclusion
==========

Our pilot analysis shows that PDW is associated with survival in patients with COPD. As it can be simply and rapidly measured from routine blood examination, should our results be confirmed in larger samples, it may prove to be a widely available, inexpensive, and repeatable prognostic marker. Furthermore, it might contribute to the characterization of the phenotypic variability of COPD.
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![Flow chart of patient selection for inclusion in the study.\
**Abbreviation:** PFT, pulmonary function test.](copd-12-2261Fig1){#f1-copd-12-2261}

![Kaplan--Meier curves for normal and elevated PDW values.\
**Abbreviation:** PDW, platelet distribution width.](copd-12-2261Fig2){#f2-copd-12-2261}

###### 

Baseline values of the study population

  Parameter                    Mean                                                95% CI
  ---------------------------- --------------------------------------------------- -----------------
  WBC (×10\^3/µL)              7.06                                                6.63, 7.49
  Neutrophils (×10\^3/µL)      4.26                                                3.89, 4.63
  Lymphocytes (×10\^3/µL)      2.08                                                1.87, 2.3
  Platelet count (×10\^3/µL)   224.1                                               202.58, 245.55
  MPV (fL)                     10.91                                               10.69, 11.13
  PDW (fL)                     13.36                                               12.9, 13.8
  PLR                          123.13                                              108.82, 137.44
  Pre-bronchodilator                                                               
   VC (L)                      2.49                                                2.3, 2.67
   FVC (L)                     2.47                                                2.28, 2.65
   FVC (%)                     76.09                                               72, 80.17
   FEV~1~ (L)                  1.47                                                1.33, 1.6
   FEV~1~ (%)                  59.29                                               54.92, 63.67
   FEV~1~/FVC                  0.59                                                0.57, 0.61
   FEF 25--75 (L/s)            0.7                                                 0.62, 0.78
   FEF 25--75 (%)              36.1                                                32.35, 39.86
   PEF (L)                     3.68                                                3.32, 4.04
   PEF (%)                     45.57                                               41.62, 49.52
  Post-bronchodilator                                                              
   VC (L)                      2.7                                                 2.52, 2.89
   FVC (L)                     2.68                                                2.5, 2.87
   FVC (%)                     82.78                                               78.84, 86.73
   FEV~1~ (L)                  1.62                                                1.48, 1.75
   FEV~1~ (%)                  65.29                                               60.9, 69.67
   FEV~1~/FVC                  0.6                                                 0.57, 0.62
   FEF 25--75 (L/s)            0.996                                               0.89, 1.1
   FEF 25--75 (%)              54.5                                                47.37, 61.62
   PEF (L)                     4.01                                                3.66, 4.36
   PEF (%)                     51.91                                               46.66, 57.16
  TLC (L)                      4.89                                                4.63, 5.15
  RV (L)                       2.42                                                2.27, 2.57
                                                                                   
                               **Number of patients**                              **Percent (%)**
                                                                                   
  Comorbidities                71                                                  89.9
   Respiratory                 14                                                  17.7
   Cardiovascular              63                                                  79.7
   Mental                      9                                                   11.4
   Endocrine system            11                                                  13.9
   Central nervous system      10                                                  12.7
   Diabetes mellitus type 2    18                                                  22.8
   Other                       47                                                  59.5
  Smoking history                                                                  
   Smoker                      18/72[a](#tfn1-copd-12-2261){ref-type="table-fn"}   25
   Non-smoker                  9/72[a](#tfn1-copd-12-2261){ref-type="table-fn"}    12.5
   Ex-smoker                   45/72[a](#tfn1-copd-12-2261){ref-type="table-fn"}   62.5
  GOLD                                                                             
   I stage                     20                                                  25.3
   II stage                    39                                                  49.4
   III stage                   17                                                  21.5
   IV stage                    3                                                   3.8

**Note:**

Smoking history was reported in 72 records.

**Abbreviations:** FEF 25--75, forced expiratory flow between 25% and 75% of vital capacity; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global initiative for chronic Obstructive Lung Disease; MPV, mean platelet volume; PDW, platelet distribution width; PEF, peak expiratory flow; PLR, platelet-to-lymphocyte ratio; RV, residual volume; TLC, total lung capacity; VC, vital capacity; WBC, white blood count.

###### 

Functional and demographic parameters of the study population according to upper limit of PDW values

  Parameter                                                      PDW ≤16 (fL) n=69                         PDW \>16 (fL) n=10                        Mean difference   Comparison result   
  -------------------------------------------------------------- ----------------------------------------- ----------------------------------------- ----------------- ------------------- --------------------------------------------------
  Age (years)                                                    73.57                                     74.1                                                                            0.64[a](#tfn3-copd-12-2261){ref-type="table-fn"}
  WBC (×10\^3/µL)                                                7.05                                      7.15                                                                            0.89[a](#tfn3-copd-12-2261){ref-type="table-fn"}
  Neutrophils (×10\^3/µL)                                        4.28                                      4.14                                      0.15              −0.97, 1.26         0.8
  Lymphocytes (×10\^3/µL)                                        2.05                                      2.26                                                                            0.63[a](#tfn3-copd-12-2261){ref-type="table-fn"}
  Platelet count (×10\^3/µL)                                     229.94                                    183.5                                     46.44             −17.74, 110.63      0.15
  MPV (fL)                                                       10.68                                     12.52                                     −1.84             −2.36, −1.32        \<0.001
  PLR                                                            125.34                                    107.89                                                                          0.42[a](#tfn3-copd-12-2261){ref-type="table-fn"}
  VC (L)[b](#tfn4-copd-12-2261){ref-type="table-fn"}             2.67                                      2.9                                       −0.23             −0.79, 0.32         0.4
  FVC (L)[b](#tfn4-copd-12-2261){ref-type="table-fn"}            2.65                                      2.89                                      −0.24             −0.8, 0.32          0.4
  FVC (%)[b](#tfn4-copd-12-2261){ref-type="table-fn"}            82.64                                     83.8                                      −1.17             −13.1, 10.76        0.85
  FEV~1~ (L)[b](#tfn4-copd-12-2261){ref-type="table-fn"}         1.59                                      1.82                                      −0.23             −0.65, 0.18         0.26
  FEV~1~ (%)[b](#tfn4-copd-12-2261){ref-type="table-fn"}         64.69                                     69.37                                     −4.68             −17.9, 8.54         0.48
  FEV~1~/FVC[b](#tfn4-copd-12-2261){ref-type="table-fn"}         0.6                                       0.57                                                                            0.2[a](#tfn3-copd-12-2261){ref-type="table-fn"}
  FEF 25--75 (L/s)[b](#tfn4-copd-12-2261){ref-type="table-fn"}   1.04                                      0.69                                      0.35              0.11, 0.59          0.007
  FEF 25--75 (%)[b](#tfn4-copd-12-2261){ref-type="table-fn"}     57.27                                     35.4                                      21.87             8.16, 35.58         0.003
  PEF (L/s)[b](#tfn4-copd-12-2261){ref-type="table-fn"}          4.13                                      3.17                                      0.96              0.32, 1.61          0.005
  PEF (%)[b](#tfn4-copd-12-2261){ref-type="table-fn"}            53.85                                     38.54                                     15.31             6.82, 23.78         \<0.001
  TLC (L)                                                        4.9                                       4.79                                      0.11              −0.64, 0.88         0.76
  RV (L)                                                         2.39                                      2.65                                                                            0.25[a](#tfn3-copd-12-2261){ref-type="table-fn"}
                                                                                                                                                                                           
                                                                 **Number of patients and percent n=69**   **Number of patients and percent n=10**                                         ***P*-value**
                                                                                                                                                                                           
  Gender                                                                                                                                                                                   0.51
   Male                                                          44 (63.77%)                               8 (80%)                                                                         
   Female                                                        25 (36.23%)                               2 (20%)                                                                         
  Smoking history                                                63                                        9                                                                               0.91
   Smoker                                                        15 (23.81%)                               3 (33.3%)                                                                       
   Non-smoker                                                    8 (12.7%)                                 1 (11.1%)                                                                       
   Ex-smoker                                                     40 (63.49%)                               5 (55.6%)                                                                       
  GOLD stages of airway obstruction                                                                                                                                                        0.90
   I                                                             16 (23.19%)                               4 (40%)                                                                         
   II                                                            35 (50.72%)                               4 (40%)                                                                         
   III                                                           15 (21.74%)                               2 (20%)                                                                         
   IV                                                            3 (4.35%)                                 0                                                                               
  Comorbidities                                                                                                                                                                            
   Respiratory                                                   13 (18.84%)                               1 (10%)                                                                         0.81
   Cardiovascular                                                55 (79.71%)                               8 (80%)                                                                         0.98
   Mental                                                        8 (11.59%)                                1 (10%)                                                                         0.88
   Endocrine system                                              9 (13.04%)                                2 (20%)                                                                         0.92
   Central nervous system                                        10 (14.49%)                               0                                                                               0.44
   Diabetes mellitus type 2                                      16 (23.19%)                               2 (20%)                                                                         0.82
   Other                                                         40 (57.97%)                               7 (70%)                                                                         0.7

**Notes:**

*P*-value for Mann--Whitney *U* test.

Post-bronchodilator values.

**Abbreviations:** FEF 25--75, forced expiratory flow between 25% and 75% of vital capacity; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global initiative for chronic Obstructive Lung Disease; MPV, mean platelet volume; PDW, platelet distribution width; PEF, peak expiratory flow; PLR, platelet-to-lymphocyte ratio; RV, residual volume; TLC, total lung capacity; VC, vital capacity; WBC, white blood count.
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